HSandM Magazine

Menu
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
Menu

HSandM Magazine

Search

Jan/Feb2016

Latest stories

Lights…Camera…Sales!

BY THE NUMBERS

Driving Down Healthcare Costs

More stories

  • in Industry Trends

    Orphan Drugs Set to Outpace Industry

    by hsandm January 1, 2016, 12:00 pm

  • in Great Minds

    MEET OUR LEAD PANELIST

    by hsandm January 1, 2016, 12:00 pm

  • in Executive Spotlight

    Outside In

  • in Innovation Showcase

    HOW AM I DOING? Annual Compensation Survey

    by hsandm January 1, 2016, 12:00 pm

  • in Industry Trends, Uncategorized

    The Why of Winning Business

    by hsandm January 1, 2016, 12:00 pm

  • in Round Table

    MEET OUR OTHER EXPERTS

    by hsandm January 1, 2016, 12:00 pm

  • in Motivideos

    MOTIVIDEOS

    by hsandm January 1, 2016, 12:00 pm

Trending Now

  • Headlines

    353 Views0 Comments

    in Headlines

    Insulin device maker brings in $115M to launch J&J-licensed product

    Marlborough, MA, April 14 2021, Marlborough-based CeQur, a maker of insulin delivery devices, has raised $115 million in capital as it gears up to launch its wearable insulin injector later this year. More

    by hsandm April 14, 2021, 3:53 pm

    Read More

  • Headlines

    438 Views0 Comments

    in Headlines

    Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors

    Boston, MA, April 13, 2021 (PRNewswire) — Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, emerged from stealth today announcing the close of a $100 million Series B financing led by Foresite Capital. Theseus also announced data from a poster presentation at the American Association for Cancer Research (AACR) 2021 Annual Meeting, which demonstrated that the Company’s lead product candidate, THE-630, has potent activity against all major classes of activating and resistance mutations observed in patients with KIT-mutant gastrointestinal stromal tumors (GIST). More

    by hsandm April 13, 2021, 3:59 pm

    Read More

  • Headlines

    516 Views0 Comments

    in Headlines

    Amarin Appoints Karim Mikhail to succeed John Thero as President and CEO

    Dublin, Ireland and Bridgewater, N.J., April 12, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, 60, has informed the board of directors of his plan to retire as president and chief executive officer, effective August 1, 2021. He will also step down from the board at that time. The board has appointed Karim Mikhail, 50, Amarin’s senior vice president and head of commercial for Europe, to succeed Mr. Thero as the company’s next president and chief executive officer. Mr. Mikhail will join the board upon his effective date. Mr. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021. More

    by hsandm April 12, 2021, 3:43 pm

    Read More

  • Headlines

    561 Views0 Comments

    in Headlines

    DiaSorin to acquire Luminex Corporation for approximately USD 1.8 billion

    Saluggia,, Italy, April 11, 2021 (PRNewswire) — DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex”;NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction. This corresponds to a total equity value of approximately USD 1.8 billion on a fully diluted basis and an enterprise value of approximately USD 1.8 billion. More

    by hsandm April 11, 2021, 7:09 pm

    Read More

  • Headlines

    896 Views0 Comments

    in Headlines

    Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO

    Brisbane, CA. and St. Louis, April 07, 2021 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member. More

    by hsandm April 7, 2021, 3:57 pm

    Read More

  • Headlines

    1.4k Views0 Comments

    in Headlines

    Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Management

    Rockville, MD, April 2, 2021 (PRNewswire) — Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management. More

    by hsandm April 2, 2021, 8:34 pm

    Read More

Categories

  • Agency Directory
  • Digital Magazine
  • Editorial Board
  • Executive Spotlight
  • Great Minds
  • Headlines
  • Industry Trends
  • Innovation Showcase
  • Leadership
  • Motivideos
  • Round Table
  • Talent Trends
  • Top Industry Lists
  • Uncategorized
  • Why I Work in Healthcare

© 2021 by CL Media, Inc.

  • Home
  • Contact us
  • Privacy Policy
  • Terms of Use
  • Sign Up!
Back to Top
Close
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
  • facebook
  • twitter
  • instagram
  • pinterest
  • youtube

Log In

Sign In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

To use social login you have to agree with the storage and handling of your data by this website. %privacy_policy%

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.